MD Biosciences is a pre-clinical contract research organization (CRO) providing in vitro and in vivo nonclinical efficacy studies as well as a clinical biomarker and general chemistry analysis. The company’s focus is on inflammation, neurological and cardiovascular conditions. MD BioSciences’ approach is to understand the need in the clinic and work backwards. In this way, the company can develop new methods for preclinical testing as well as new biomarkers that can be used in the clinical setting to improve upon current methods. Other CRO companies who have set up facilities in China or established M&As are Quintiles, Covance, PPD, CRL and ICON. Visit MD Biosciences at G17 in Hall A.